TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive NCI, American Cancer Society Re-Evaluating Join Guidelines On Mammography Screening September 17, 1993
TCL Archive CCOP Review Competed, Enough Good Applications In Funding Range To Get Viable Program Started February 18, 1983
TCL Archive NCI Intramural Programs: Clinical Trials Support System Need Attention, report Advises DCS December 19, 1997
